Japanese encephalitis vaccine - Shandong Hengye Biotech

Drug Profile

Japanese encephalitis vaccine - Shandong Hengye Biotech

Alternative Names: Vero cell-derived inactivated Japanese encephalitis vaccine - Shandong Hengye Biotech

Latest Information Update: 19 Sep 2016

Price : $50

At a glance

  • Originator Shandong Hengye Biotech
  • Developer Jiangsu Provincial Center for Disease Control and Prevention; Shandong Hengye Biotech
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Japanese encephalitis

Most Recent Events

  • 01 Oct 2014 Phase-III clinical trials in Japanese encephalitis (In infants, Prevention) in China (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top